SEOUL -- Daewoong Pharmaceutical, a major bioengineering company in South Korea, has secured approval to sell Nabota, a botulinum toxin product for the treatment of frown lines, in Indonesia and the United Arab Emirates. Nabota secured approval from the U.S. Food and Drug Administration in February this year.
Daewoong said that Nabota will be available in Indonesia and the UAE in the first half of 2020. Dansys based in Dubai has been selected as the exclusive distributor of Navota in eight Middle East countries. "As a hub country in the Middle East, the UAE can play a bridging role when we move into other regions, while Indonesia has great potential for growth as the world's fourth-largest population power," said Daewoong’s Nabota business head Park Sung-soo.
The greenlight in Indonesia and the UAE came after Daewoong scored a partial victory in the preliminary round of a botox patent war with its domestic rival, Medytox, over the origin of strains. Medytox has filed lawsuits in U.S. and South Korean courts, claiming that Daewoong has violated trade secrets by recruiting a former Medytox employee to steal information on strains and manufacturing.
Botulinum toxin is a neurotoxic protein produced by the bacterium Clostridium botulinum and related species. Medytox insisted its botulinum strain type A "Meditoxin" cannot be found in a natural state because it does not form spores, while Daewoong said the strain was sporiferous and found in a stable.
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.